Autopsy report · NCT02028026

The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives

“Inability to recruit eligible subjects”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

Massachusetts General Hospital

Sponsor type

University, hospital or other

Conditions

Major Depressive Disorder; Anxiety; Comorbidity

Interventions

Vilazodone; Citalopram

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan
  “inability to recruit subjects” (90% match in meaning)
• In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity
  “Not able to recruit subjects” (86% match in meaning)
• A Pilot and Feasibility Study of Fecal Microbiota Transplantation for Ulcerative Colitis
  “Unable to recruit and enroll eligible subjects.” (85% match in meaning)
• The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema
  “Difficulty enrolling eligible subjects” (85% match in meaning)
• Prospective Evaluation of Symptom Resolution in Acid Versus Non-acid Reflux Disease Following Anti-reflux Surgery
  “Unable to recruit a sufficient number of subjects.” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.